We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC™ technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Data Provided by Refinitiv. Minimum 15 minutes delayed.
11-17-2021 2:40 PM EST
10-13-2021 10:30 AM EDT
09-16-2021 6:30 AM EDT